Title:Prevalence of Anemia among Chronic Myeloid Leukemia Patients Treated
with Imatinib: A Evidence-based Meta-analysis
Volume: 18
Issue: 2
Author(s): Avinash Kumar Singh, Anoop Kumar, Narendra Agrawal, Dinesh Bhurani, Rayaz Ahmed and Manju Sharma*
Affiliation:
- Department of Pharmacology, School of Pharmaceutical Education and Research,
Jamia Hamdard, New Delhi-110062, India
Keywords:
Hemoglobin, meta-analysis, blood cancer, tyrosine kinase inhibitors, incidence, imatinib.
Abstract:
Background: Imatinib is one of the tyrosine kinase inhibitors used for the treatment of
chronic myeloid leukemia (CML) patients. The exact association of imatinib with anemia in CML patients
is still unclear.
Aim: The current study aimed to find the prevalence of anemia in chronic myeloid leukemia patients
treated with imatinib.
Methods: The relevant articles were searched in PubMed, Google scholar, and Clinical trials registries
till 31st July, 2021. The quality of the articles was assessed using the Newcastle-Ottawa Scale. The
prevalence rate with 95% CI was calculated using StatsDirect Statistical analysis software V.3.
Results: A total of 18 studies containing 3537 patients were found relevant for the analysis. The
pooled prevalence of anemia in CML was found to be 34% (95% CI: 23%-46%). However, the heterogeneity
among studies was found to be high.
Conclusion: The monitoring of hemoglobin levels and identifying the cause of anemia are major concerns
for the CML patients treated with Imatinib.